MedTrace Logo

Open Registry Measuring Impact of Genomic Testing on Treatment of Prostate Cancer Patients

NCT01954004 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1270

Last updated 2015-06-02

No results posted yet for this study

Summary

This registry is intended to evaluate the impact of genomic test results towards selecting a first-line therapy option for newly diagnosed localized prostate cancer patients.

Conditions

Sponsors & Collaborators

  • Myriad Genetic Laboratories, Inc.

    lead INDUSTRY

Principal Investigators

  • Richard Wenstrup, MD · Myriad Genetic Laboratories, Inc.

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01954004 on ClinicalTrials.gov